News Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
2.85 ^USD	-1.04%		-14.67%	+22.84%

Mar. 20	North American Morning Briefing : Markets on Hold -2-	DJ
Mar. 19	JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 04	AQ
North American Morning Briefing : Markets on Hold -2-	Mar. 20	DJ
JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5	Mar. 19	MT
Mersana Therapeutics, Inc.(NasdaqGS:MRSN) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
Truist Securities Upgrades Mersana Therapeutics to Buy From Hold, Price Target is $9	Feb. 29	MT
Guggenheim Upgrades Mersana Therapeutics to Buy From Neutral, Price Target is $7	Feb. 29	MT
Wedbush Upgrades Mersana Therapeutics to Outperform From Neutral, Notes Increased Confidence in Program; Adjusts PT to $7 From $2	Feb. 29	MT
Transcript : Mersana Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q4 Revenue $10.7M, vs. Street Est of $14.8M	Feb. 28	MT
Mersana Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results	Feb. 28	AQ
Mersana Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Mersana Therapeutics to Present at Upcoming Investor Conferences	Feb. 27	AQ
Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024	Feb. 21	AQ
Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference	Feb. 01	AQ
Transcript : Mersana Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 11:15 AM	Jan. 11
Mersana Therapeutics Gears Up for Milestones in Cancer Drug Trials	Jan. 05	MT
Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 05	AQ
Mersana Therapeutics, Inc. Announces Business Updates	Jan. 05	CI
Mersana Therapeutics : Termination of Material Agreement - Form 8-K	Dec. 21	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Summary

Filters